Blood filter showdown: which method clears harmful antibodies faster?

NCT ID NCT03635385

Completed Knowledge-focused Sponsor: Assistance Publique Hopitaux De Marseille Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study compares two blood-filtering techniques—plasma exchange and immunoadsorption—in 40 patients with severe kidney failure caused by ANCA vasculitis or Goodpasture disease. The goal is to see which method removes disease-causing antibodies more quickly. Results may help doctors choose the best approach for rapid treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Apheresis techniques (plasma exchange and immunoadsorption)
What this could lead to: If this study shows one method removes harmful antibodies faster, it could guide doctors to choose the better technique for severe kidney or lung disease.
What could go wrong: This is a small pilot study with only 40 participants, so results may not apply to all patients. It does not test long-term outcomes or survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANCA-ASSOCIATED VASCULITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute kidney injury anti-basement membrane glomerulonephritis anti-glomerular basement membrane disease granulomatosis with polyangiitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KIDNEY FAILURE, ACUTE

Contacts and locations

Locations

Assisatance Publique Hôpitaux de Marseille

Marseille, 13354, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.